Drugs / DS-1093a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02299661 | Nov 2014 → May 2015 | anemia, chronic kidney disease | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1093a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02299661 ↗ |
| Action | Inhibit | “DS-1093a is an inhibitor of hypoxia-inducible factor prolyl hydroxylases” NCT02299661 ↗ |
| Route | Oral | “DS-1093a, single oral doses up to 50 mg” NCT02299661 ↗ |